Friday: The FDA Drops the Hammer On February 6th, one day after the HIMS launch, FDA Commissioner Martin Makary issued a statement that may be the most consequential regulatory action in the compounded GLP-1 saga to date
In 2023, Black adults received only about 12 percent of prescriptions for popular anti-obesity drugs, while 85 percent went to White patients.21 This stark disparity underscores systemic inequities in the healthcare system, from provider bias to financial barriers, that disproportionately affect communities of color
However, with dual or triple agonists, the hyperglycemic influence of GCG is expected to be mitigated by the hypoglycemic actions of GIP and GLP-1
Get in touch Contact Us 3622 Galileo Dr, Suite #102 New Port Richey, Fl 34655 Call or Text
It contains liraglutide, a GLP-1 receptor agonist
Love how fast it works with no side effects Slowly seeing progress but not doing anything extra and still getting results Amazing product